News
Ascletis Submits Two US FDA IND Applications for Novel Obesity Therapies
Last month, Ascletis received US FDA IND clearance to initiate a Phase I clinical trial evaluating its once-monthly Self-Assembling Lipid Depot (SALD) formulation of ASC35 as a subcutaneous treatment for obesity.
imphoenix82
- July 6, 2026
- 0 Comments
- 10 Views
-
